Diagnostic performance of microvascular flow imaging for noninvasive assessment of liver fibrosis in chronic liver disease
PLOS One · 2025
DOI: 10.1371/journal.pone.0322102 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Hae Won Yoo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Gastroenterology and Hepatology, Soon Chun Hyang University Bucheon Hospital, Bucheon, Korea. Hauptthemen laut MEDLINE: Liver Cirrhosis, Microvessels, Liver Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Samsung Medison, Soonchunhyang University.
Abstract (Originalsprache)
Background and aims Chronic liver disease (CLD) represents a significant global health challenge necessitating the evaluation of liver fibrosis. This study aimed to evaluate the diagnostic performance of microvascular flow (MV-flow) imaging in evaluating liver fibrosis and compare it with other non-invasive tools.
Methods
Between July 2020 and June 2022, we prospectively enrolled patients scheduled for liver biopsy, concurrently measuring MV-flow imaging, transient elastography (TE), and two-dimensional shear wave elastography (2D-SWE) as part of the assessment process. We evaluated the diagnostic performance of MV-flow imaging, 2D-SWE, and TE based on histologic staging of liver fibrosis using the area under the receiver operating characteristic curve (AUROC), and calculated the optimal cut-off value.
Results
A total of 89 participants were included. Non-alcoholic fatty liver disease was the most common etiology of CLD (32.6%). The liver fibrosis stage distribution was as follows: stage 0 (11.2%), stage 1 (31.5%), stage 2 (25.8%), stage 3 (13.5%), and stage 4 (18.0%). The MV-flow scoring system’s cut-off values and AUROCs for predicting stage 2, stage 3, and cirrhosis were 2.1 (0.836), 2.5 (0.955), and 2.9 (0.942), respectively. The MV-flow scoring system’s performance in predicting advanced fibrosis (stage 3) was comparable to TE ( p = 0.170) and 2D-SWE ( p = 0.456). MV-flow imaging misclassified 9.0% of patients in predicting advanced fibrosis. A sequential combination of 2D-SWE and MV-flow imaging, following the specified cut-off, minimized the risk of missing advanced fibrosis to 1.2%.
Conclusion
MV-flow imaging is an effective tool for predicting liver fibrosis stage. Integrating MV-flow imaging with 2D-SWE can enhance the assessment of liver fibrosis in patients with CLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Gastroenterology and Hepatology, Soon Chun Hyang University Bucheon Hospital, Bucheon, Korea.
- Department of Internal Medicine, Soon Chun Hyang University Seoul Hospital, Seoul, Korea.
- Department of Internal Medicine, Soon Chun Hyang University Chunan Hospital, Chunan, Korea.
- Department of Internal Medicine, Gangneung Asan Hospital, Gangneung, Korea.
ORCID-Profile: Young Seok Kim, Sang Gyune Kim
Förderung
- Samsung Medison
- Soonchunhyang University
Zitieren
APA
Yoo, H. W., Yang, C. J., Yoo, J. J., Chang, Y., Lee, S. H., Jeong, S. W., Jang, J. Y., Cheon, G. J., Kim, Y. S., Kim, H. S., & Kim, S. G. (2025). Diagnostic performance of microvascular flow imaging for noninvasive assessment of liver fibrosis in chronic liver disease. PLOS One. https://doi.org/10.1371/journal.pone.0322102
Vancouver
Yoo HW, Yang CJ, Yoo JJ, Chang Y, Lee SH, Jeong SW, et al. Diagnostic performance of microvascular flow imaging for noninvasive assessment of liver fibrosis in chronic liver disease. PLOS One. 2025. doi:10.1371/journal.pone.0322102
BibTeX
@article{Yoo2025,
author = {Yoo, Hae Won and Yang, Chan Jin and Yoo, Jeong-Ju and Chang, Young and Lee, Sae Hwan and Jeong, Soung Won and Jang, Jae Young and Cheon, Gab Jin and Kim, Young Seok and Kim, Hong Soo and Kim, Sang Gyune},
title = {Diagnostic performance of microvascular flow imaging for noninvasive assessment of liver fibrosis in chronic liver disease},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0322102}
}
EUVIMED